+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.

Age: 18Years +All GendersPhase 3
284 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
C

Actively Recruiting

Researchers are evaluating two treatment approaches for patients with high anatomic stage breast cancer that has a low risk of returning. This phase III trial compares standard hormone therapy combined with ribociclib to chemotherapy followed by hormone therapy and ribociclib. Ribociclib works by blocking enzymes needed for tumor growth, and hormone therapy reduces estrogen levels to help stop the growth of cancer cells that depend on estrogen. Chemotherapy works differently by killing or stopping the division and spread of tumor cells. Participants are first screened using the Oncotype DX test to assess their recurrence risk. Those with scores between 0 and 25 are randomized into one of two groups. One group receives their physicians choice of chemotherapy followed by hormone therapy letrozole, anastrozole, or exemestane plus ribociclib. The other group receives hormone therapy plus ribociclib without chemotherapy. Hormone therapy is taken daily for at least 60 months, and ribociclib is taken daily for up to 3 years unless disease progression or unacceptable side effects occur. Throughout the study, participants may undergo imaging scans such as CT, bone scans, or FDG PET-CT scans, and may optionally provide blood samples. Participants are monitored with follow-up visits every 3 months for the first year, every 6 months during years 1 to 5, and annually from years 5 to 10 after randomization. Researchers will assess invasive breast cancer-free survival as the main outcome, along with disease-free survival, overall survival, recurrence measures, and both short- and long-term side effects. The study also plans to collect tumor tissue and blood samples to support future research. Total participation may last up to 10 years to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
248 locations